TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Core Insights - TG Therapeutics, Inc. announced the presentation schedule for BRIUMVI (ublituximab-xiiy) data at the American Academy of Neurology 2025 annual meeting, focusing on its efficacy in treating relapsing forms of multiple sclerosis (RMS) [1] Company Overview - TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, with BRIUMVI approved for RMS treatment in the U.S., Europe, and the UK [24] - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed to efficiently deplete B-cells at low doses through glycoengineering [5] Clinical Trials - The ULTIMATE I & II trials are Phase 3 studies involving 1,094 RMS patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [3][4] - The upcoming presentations will include various studies on BRIUMVI's long-term effects, infusion tolerability, and real-world efficacy [2] Presentation Details - Presentations will cover topics such as the association between serum immunoglobulin levels and serious infections, infusion tolerability, and results from the ULTIMATE studies [2][3] - Key presentations are scheduled for April 7 and April 9, 2025, at the AAN meeting [3]